Preferred Label : Revumenib Citrate;
NCIt synonyms : Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-N-(1-methylethyl)-,
2-Hydroxy-1,2,3-propanetricarboxylate, Hydrate (1:1:1); Revumenib Monocitrate Monohydrate;
NCIt related terms : Revumenib;
NCIt definition : The monocitrate monohydrate form of revumenib, an orally bioavailable protein-protein
interaction (PPI) inhibitor of menin with both wild-type and fusion proteins of lysine
methyltransferase 2A (mixed lineage leukemia MLL; myeloid/lymphoid leukemia; KMT2A),
with potential antineoplastic activity. Upon oral administration, revumenib targets
and binds to the nuclear protein menin, thereby preventing the interaction between
the two proteins menin and KMT2A and the formation of the menin-KMT2A complex. This
reduces the expression of downstream target genes and results in an inhibition of
the proliferation of KMT2A-rearranged leukemic cells. The menin-KMT2A complex induces
the transcription of various genes involved in the survival, growth, transformation
and proliferation of certain kinds of leukemia cells.;
UNII : YL4RYN734D;
CAS number : 2761046-45-9;
Drug name : Revuforj;
NCI Metathesaurus CUI : CL1926394;
Origin ID : C204149;
UMLS CUI : C5909619;
Semantic type(s)
- concept_is_in_subset
- has_free_acid_or_base_form
- is_component_of_chemotherapy_regimen
- is_salt_form_of
